findmyKOL

Charles Eisenbeis, MD

Basic profile

McKesson

ORCIDNone on fileNPI
RegionCary, NC · SoutheastSpecialtyHematology / OncologyFocusOncology
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2017Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Charles Eisenbeis is an Oncology physician affiliated with McKesson. OpenAlex indexes 22 publications with 1,614 citations (h-index 16).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
22publications

Distinct works indexed by OpenAlex.

1,614citations

Total citations across indexed works.

16h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

150 Parkway Office Ct Ste 200
Cary, NC 275180002

Telephone

984-974-2150

Provider last certified this registry record 10 Jan 2023.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    32.5%
    Phenothiazine12.2%
    Prochlorperazine Maleate100%
    Part D33 patients
    Other antidepressants4.6%
    Mirtazapine100%
    Part D<11 patients

    + 5 more classes in this area

  • Cancer & immunology

    20.3%
    Kinase inhibitor9.2%
    Ibrance46%Alecensa28%Calquence26%
    Part D<11 patients
    Antimetabolite4.8%
    Hydroxyurea100%
    Part D11 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    19.5%
    Proton pump inhibitor8.2%
    Omeprazole61%Pantoprazole Sodium39%
    Part D<11 patients
    Serotonin-3 Receptor Antagonist8%
    Ondansetron Hcl100%
    Part D24 patients

    + 1 more class in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”